5433222025-01-012025-03-315433222025-03-315433222024-03-315433222024-04-012025-03-315433222025-01-012025-03-31in-capmkt:OtherExpenses1Member5433222024-04-012025-03-31in-capmkt:OtherExpenses1Member5433222025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15433222024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15433222025-01-012025-03-31RelatedPartyTransactionDomain15433222024-12-31RelatedPartyTransactionDomain15433222025-03-31RelatedPartyTransactionDomain15433222025-01-012025-03-31RelatedPartyTransactionDomain25433222024-12-31RelatedPartyTransactionDomain25433222025-03-31RelatedPartyTransactionDomain25433222025-01-012025-03-31RelatedPartyTransactionDomain35433222024-12-31RelatedPartyTransactionDomain35433222025-03-31RelatedPartyTransactionDomain35433222025-01-012025-03-31RelatedPartyTransactionDomain45433222024-12-31RelatedPartyTransactionDomain45433222025-03-31RelatedPartyTransactionDomain45433222025-01-012025-03-31RelatedPartyTransactionDomain55433222024-12-31RelatedPartyTransactionDomain55433222025-03-31RelatedPartyTransactionDomain55433222025-01-012025-03-31RelatedPartyTransactionDomain65433222024-12-31RelatedPartyTransactionDomain65433222025-03-31RelatedPartyTransactionDomain65433222025-01-012025-03-31RelatedPartyTransactionDomain75433222024-12-31RelatedPartyTransactionDomain75433222025-03-31RelatedPartyTransactionDomain75433222025-01-012025-03-31RelatedPartyTransactionDomain85433222024-12-31RelatedPartyTransactionDomain85433222025-03-31RelatedPartyTransactionDomain85433222025-01-012025-03-31RelatedPartyTransactionDomain95433222024-12-31RelatedPartyTransactionDomain95433222025-03-31RelatedPartyTransactionDomain95433222025-01-012025-03-31RelatedPartyTransactionDomain105433222024-12-31RelatedPartyTransactionDomain105433222025-03-31RelatedPartyTransactionDomain105433222025-01-012025-03-31RelatedPartyTransactionDomain115433222024-12-31RelatedPartyTransactionDomain115433222025-03-31RelatedPartyTransactionDomain115433222025-01-012025-03-31RelatedPartyTransactionDomain125433222024-12-31RelatedPartyTransactionDomain125433222025-03-31RelatedPartyTransactionDomain125433222025-01-012025-03-31RelatedPartyTransactionDomain135433222024-12-31RelatedPartyTransactionDomain135433222025-03-31RelatedPartyTransactionDomain135433222025-01-012025-03-31RelatedPartyTransactionDomain145433222024-12-31RelatedPartyTransactionDomain145433222025-03-31RelatedPartyTransactionDomain145433222025-01-012025-03-31RelatedPartyTransactionDomain155433222024-12-31RelatedPartyTransactionDomain155433222025-03-31RelatedPartyTransactionDomain155433222025-01-012025-03-31RelatedPartyTransactionDomain165433222024-12-31RelatedPartyTransactionDomain165433222025-03-31RelatedPartyTransactionDomain165433222025-01-012025-03-31RelatedPartyTransactionDomain175433222024-12-31RelatedPartyTransactionDomain175433222025-03-31RelatedPartyTransactionDomain175433222025-01-012025-03-31RelatedPartyTransactionDomain185433222024-12-31RelatedPartyTransactionDomain185433222025-03-31RelatedPartyTransactionDomain185433222025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543322ALIVUSNOTLISTEDINE03Q201024Alivus Life Sciences LimitedMain BoardEquity2024-04-012025-03-312025-05-152025-05-08INRMillionsQuarterlyFourth quarterSingle segmentActive Pharmaceutical Ingredient (API)2025-05-1517:00:002025-05-1518:45:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-01-23https://bunny-wp-pullzone-zhbiessutg.b-cdn.net/alivus_pdfs/investors/corporate_governance/Policy%20on%20related%20party%20transactions%20and%20its%20materiality.pdffalsefalseThe Company is a debt free Company2025-01-012025-03-31AuditedStandalone6495450000100880000659633000028045400000214200006672200001260000015970000010179500004683430000191290000001912900000478770000154500004942200000141868000000001418680000-15100001417170000245070000211.5711.550011.5711.552024-04-012025-03-31AuditedStandalone238688400003457000002421454000010535020000027350000025169600002414000060609000037175200001767323000065413100000654131000016244000006064000016850400000485627000000004856270000-12480000484379000024507000022792865000039.6339.520039.6339.52Other Expenses1017950000Other Expenses37175200009426700000942520000012276000076610000770000063740000645100001298500001076295000067394600004776150000969741000071062000017400000398650000155845700001027550000233515800000034114530000245070000279286500002817372000028173720000050958000050958000018535000054429000012392200000134050000377059000039046400004611100004365750000166270000169570000470159000059408100003411453000024140000-388550000-2047890000044520000000001874600000006060900000937700000002149000002001300000-7615000001821000003198100000-996550000554476000000016295200000391524000000000000629000016618700000000000000000000002001300000-4701000000-615645000000669000000000004486000002414000000-62310000-23035200000-23035200003014140000710620000Re-measurement of the post-employment benefit obligation-2270000-2270000Re-measurement of the post-employment benefit obligation-16680000-16680000-760000-4200000-1510000-12480000Alivus Life Sciences Limited******Glenmark Pharmaceuticals Inc., USA******Refer the notes sectionSale of goods or services550000000NA1250000002025-05-1553650000018342000087900000Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.Alivus Life Sciences Limited******Aculife Healthcare Private Limited******Fellow SubsidiarySale of goods or services2000000NA3000000Subsidiary of holding company - Nirma LimitedAlivus Life Sciences Limited******Glenmark Pharmaceuticals Ltd******Refer the notes sectionSale of goods or services10000000000NA372368000039184900004571210000Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.Alivus Life Sciences Limited******Glenmark Pharmaceuticals Inc., USA******Refer the notes sectionPurchase of goods or services100000000NA5155000000Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.Alivus Life Sciences Limited******Viso Farmaceutica S.L.U.******Refer the notes sectionPurchase of goods or services35000000NA200000002025-01-2321040000-19400000-2610000Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.Alivus Life Sciences Limited******Glenmark Farmaceutica Ltda., Brazil******Refer the notes sectionPurchase of goods or services80000000NA21960000-45090000-7840000Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.Alivus Life Sciences Limited******Glenmark Pharmaceuticals Inc., USA******Refer the notes sectionAny other transactionReimbursement of expenses0NA4219000000Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.Alivus Life Sciences Limited******Glenmark Pharmaceuticals Europe Ltd., U.K.******Refer the notes sectionAny other transactionReimbursement of expenses40000000NA0-8110000-420000Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.Alivus Life Sciences Limited******Glenmark Pharmaceuticals Ltd******Refer the notes sectionPurchase of goods or services250000000NA7036000000Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.Alivus Life Sciences Limited******Dr. Yasir Rawjee******Managing Director & CEORemuneration0NA8200000000Alivus Life Sciences Limited******Mr. Tushar Mistry******Chief Financial OfficerRemuneration0NA4086000000Alivus Life Sciences Limited******Mr. Rudalf Corriea******Company Secretary & Compliance OfficerRemuneration0NA135000000Alivus Life Sciences Limited******Mr. Vinod Naik******Executive Director & Head of the Technical OperationsRemuneration0NA3962000000Alivus Life Sciences Limited******Mrs. Manju Agarwal******Non-executive DirectorAny other transactionSitting Fees0NA70000000Alivus Life Sciences Limited******Mr. T L Easwar******Non-executive DirectorAny other transactionSitting Fees0NA70000000Alivus Life Sciences Limited******Mr. Savan Godiawala******Non-executive DirectorAny other transactionSitting Fees0NA50000000W.e.f. 25 April 2024Alivus Life Sciences Limited******Mr.Kaushikbhai Patel******Non-executive DirectorAny other transactionSitting Fees0NA50000000Alivus Life Sciences Limited******Mr.Vijaykumar Shah******Non-executive DirectorAny other transactionSitting Fees0NA50000000Upto 26th February 20254634040000AuditedtrueWalker Chandiok & Co LLPtrue2028-05-31